Guideline-Directed Medical Therapy for Chronic Kidney Disease

Core Pharmacologic Interventions

• The American Journal of Kidney Diseases recommends SGLT2 inhibitors should be initiated in all patients with CKD stages G1-G4 to slow progression and reduce cardiovascular events 2
• The American Journal of Kidney Diseases suggests that SGLT2 inhibitors provide kidney protection through multiple mechanisms, including reducing glomerular hyperfiltration and increasing diuretic efficacy 2
• The Journal of the American College of Cardiology recommends SGLT2 inhibitors prevent heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk 4
• The American College of Cardiology recommends ACE inhibitors or ARBs for all CKD patients with proteinuria, targeting a 30% or greater reduction in urinary albumin excretion 5
• The Journal of the American College of Cardiology suggests that ARBs are preferred in patients intolerant to ACE inhibitors 4
• The Kidney International recommends statin or statin/ezetimibe combination therapy for adults ≥50 years with eGFR <60 mL/min/1.73 m² 1
• The Circulation journal recommends target blood pressure <140/90 mmHg in all CKD patients to prevent progression and reduce cardiovascular events 3

Additional Therapeutic Considerations

• The American Journal of Kidney Diseases suggests that finerenone reduces cardiovascular and kidney outcomes in patients with CKD and type 2 diabetes 2
• The Kidney International recommends low-dose aspirin for secondary prevention in CKD patients with established ischemic cardiovascular disease 1
• The Kidney International suggests that non-vitamin K antagonist oral anticoagulants are preferred over warfarin for thromboprophylaxis in atrial fibrillation in CKD stages G1-G4 1

Lifestyle and Dietary Modifications

• The Kidney International recommends adopting a plant-based Mediterranean-style diet to reduce cardiovascular risk and complement pharmacologic therapy 1
• The Circulation journal suggests that regular physical activity, maintaining normal weight, and avoiding smoking reduce future risk of heart failure and CKD progression 3

Critical Implementation Strategies

• The Journal of the American College of Cardiology recommends uptitrating GDMT medications to maximally tolerated target doses rather than stopping at initial doses 4
• The American Journal of Kidney Diseases suggests that transient increases in serum creatinine and mild hyperkalemia are acceptable when initiating or uptitrating RAAS inhibitors 2

Special Populations

• The American Journal of Kidney Diseases recommends quadruple therapy, including ACE inhibitor/ARB, beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor, in patients with heart failure and reduced ejection fraction plus CKD 2
• The Kidney International suggests that NOAC dosing requires careful adjustment in advanced CKD, with consideration of warfarin in stage G5 1